Telix Pharmaceuticals (ASX:TLX) has announced a research cooperation agreement with Heidelberg University Hospital in Germany (UKHD) to develop next-generation theranostic radiopharmaceuticals for urologic oncology.
The company said under the terms of the agreement, Telix and UKHD will co-develop new conjugates and constructs for diagnostic and therapeutic (‘theranostic’) use.
"The goal of the collaboration is to identify candidates and generate sufficient data to proceed to first in human (FIH) trials, with all candidates being evaluated in a pre-clinical study (in vitro and in vivo analysis, toxicology, and manufacturing suitable for clinical translation)," said the company.
CEO Dr Chris Behrenbruch said, “We are delighted to announce this research cooperation agreement, which formalises the strengthening relationship between Telix and University Hospital Heidelberg.
"We could not be more excited by the potential of this collaboration to develop and potentially commercialise new therapeutic products to serve the needs of patients living with cancer.”
Professor Frederik Giesel, Vice-Chair of Nuclear Medicine Department at UKHD, added, “We are thrilled to dive into a deeper collaboration between Telix and UKHD to devote our expertise in possible new theranostic agents and novel radionuclide combinations to improve patient care in urologic oncology, particularly prostate cancer.”